INOTUZUMAB OZOGAMICIN | B761040 | WYETH PHARMS INC
Earliest legal licensure (12-year BPCIA floor)
The 12-year reference-product exclusivity is the non-carveable floor — the earliest FDA could license a biosimilar for any indication. Unverified estimate — derived from the earliest available approval record (Aug. 17, 2017), not an FDA-stated exclusivity date. Shown with lower confidence than a Purple Book value.
Full-label vs. best-skinny biosimilar entry
| Scenario | Date | Status | Controlling |
|---|---|---|---|
| Best-skinny entry (floor) | Aug. 17, 2029 | 3y 1mo remaining | 12-year RPE floor (non-carveable) |
| Full-label entry | Mar. 6, 2031 | 4y 7mo remaining | carveable orphan wall |
Minimal carve: Dropping the orphan-walled indication ("treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older", protected through 2031-03-06) advances biosimilar entry from the full-label date to the estimated 12-year floor.
Carve frontier · drop each orphan-walled indication to advance entry
| Drop this orphan-walled indication | Walled through | → Entry advances to |
|---|---|---|
| treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older(label indication #2) | Mar. 6, 2031 | Aug. 17, 2029(12-yr RPE floor) |
Each rung drops one orphan-designated indication (sourced from the FDA Orphan Drug Product designation database and matched to the reference label); dropping the latest-walled indication advances biosimilar entry to the next constraint, until every orphan wall is carved and entry reaches the RPE floor.
Carveable orphan wall · Mar. 6, 2031
Orphan-drug exclusivity runs past the licensure floor above, but it walls only its specific orphan-designated indication(s). A biosimilar can omit those indications (a “fewer-than-all-conditions” carve-out) and be licensed for the rest at the floor date, then add the protected indication back by supplement once the orphan period expires. It is not a licensure gate for the other indications.
Marketing-entry ceiling (litigation risk)
Patents do not gate FDA licensure of a biosimilar — FDA licenses biosimilars (full or carved label) without adjudicating any patent. These are a practical marketing-entry ceiling resolved in the § 262(l) patent dance and ordinary litigation. A formulation/compound patent caps practical skinny entry via litigation (Regeneron v. Mylan); a method-of-use patent is carveable and gates nothing.
Latest formulation/compound patent 12371507· AI-discovered, not Purple-Book-listed · relevance 70/100. This caps practical skinny-label entry; it does not move the licensure floor above.
40 formulation/compound (cap skinny entry) · 2 method-of-use (carveable — gate nothing) · 8 device/diagnostic/manufacturing
| Patent | Class | Expiration | Source |
|---|---|---|---|
| 12371507 | Formulation/compound | Jul. 24, 2045Active | Discovered |
| 12257281 | Formulation/compound | Mar. 20, 2045Active | Discovered |
| 11993625 | Formulation/compound | May. 23, 2044Active | Discovered |
| 11944689 | Formulation/compound | Mar. 28, 2044Active | Discovered |
| 11850287 | Other | Dec. 21, 2043Active | Discovered |
| 11844839 | Other | Dec. 14, 2043Active | Discovered |
| 11814435 | Formulation/compound | Nov. 9, 2043Active | Discovered |
| 11780935 | Formulation/compound | Oct. 5, 2043Active | Discovered |
| 11712480 | Formulation/compound | Jul. 27, 2043Active | Discovered |
| 11667696 | Other | Jun. 1, 2043Active | Discovered |
| 11661438 | Formulation/compound | May. 25, 2043Active | Discovered |
| 11613581 | Formulation/compound | Mar. 23, 2043Active | Discovered |
| 11576981 | Formulation/compound | Feb. 9, 2043Active | Discovered |
| 11510959 | Formulation/compound | Nov. 24, 2042Active | Discovered |
| 10941216 | Formulation/compound | Mar. 4, 2041Active | Discovered |
Showing 15 of 50 patents (latest expirations).
Disclaimer: Identifying an available carve-out is not a prediction that FDA will approve the particular carved label, nor that marketing it is free of infringement risk. For biologics, availability turns on exclusivities, not patents: FDA licenses a biosimilar (full or carved label) without adjudicating any patent, and patent disputes run through the § 262(l) patent dance and ordinary litigation, outside this availability view.
Top 50 of 66 AI-discovered patents by relevance.
No patent or exclusivity listings for this strength.